Ibritumomab tiuxetan
- Generic Name
- Ibritumomab tiuxetan
- Brand Names
- Zevalin
- Drug Type
- Biotech
- CAS Number
- 206181-63-7
- Unique Ingredient Identifier
- 4Q52C550XK
- Background
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
- Indication
For treatment of non-Hodgkin's lymphoma
- Associated Conditions
- Follicular Non-Hodgkin's Lymphoma, Follicular Non-Hodgkin's Lymphoma Refractory, Relapsed follicular B-cell non-Hodgkin's lymphoma
Zevalin-beam for Aggressive Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Procedure: BEAM chemotherapy and autologous stem-cell transplantation
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00491491
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇩🇪Georg-August Universität, Göttingen, Germany
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
- Conditions
- Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 18
- Registration Number
- NCT00453102
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
- Conditions
- Lymphoma
- Interventions
- Procedure: autologous hematopoietic stem cell harvesting and transplantation
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 20
- Registration Number
- NCT00392691
- Locations
- 🇨🇭
Saint Claraspital AG, Basel, Switzerland
🇨🇭Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭Kantonsspital Liestal, Bern, Switzerland
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
- Conditions
- Non-Hodgkin's LymphomaLymphoma
- Interventions
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00387023
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
- Conditions
- Follicular LymphomaLymphoma, Follicular
- Interventions
- Drug: R-CVP
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 26
- Registration Number
- NCT00384111
- Locations
- 🇺🇸
Integrated Community Oncology Network, Jacksonville, Florida, United States
🇺🇸Wellstar-Northwest Georgia Oncology Centers, Marietta, Georgia, United States
🇺🇸Oncology Hematology Care Inc., Cincinnati, Ohio, United States
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 18
- Registration Number
- NCT00372905
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.
- Conditions
- Lymphoma, Non-Hodgkin
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- A.O. Ospedale Papa Giovanni XXIII
- Target Recruit Count
- 25
- Registration Number
- NCT00354822
- Locations
- 🇮🇹
USC Ematologia Ospedali Riuniti di Bergamo, Bergamo, BG, Italy
🇮🇹Istituto per la Ricerca e la Cura del Cancro IRCC, Candiolo, TO, Italy
🇮🇹Medicina Nucleare ed Oncologia Medica AOU Policlinico Universitario di Messina, Messina, ME, Italy
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 68
- Registration Number
- NCT00322218
- Locations
- 🇺🇸
Research site, Detroit, Michigan, United States
🇬🇧Research Site, London, United Kingdom
🇰🇷Research Site, Yonsei, Seoul, Korea, Republic of
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
- Conditions
- Lymphoma, Small Cleaved-Cell, FollicularLymphoma, Large-Cell, FollicularLymphoma, FollicularLymphoma, Non-Hodgkin
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00319332
- Locations
- 🇺🇸
GSK Clinical Trials Call Center, Tacoma, Washington, United States
🇺🇸GSK Clinical Trial Call Center, Seattle, Washington, United States
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00290511
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.